Key result
Current literature presents conflicting evidence on the use of hormone replacement therapy in pulmonary hypertension, with no consensus established due to a lack of randomized controlled trials.
Why the study?
A paradox exists regarding the role of estrogens in pulmonary hypertension, as some research suggests hormone replacement therapy benefits women while other studies highlight its risks.
Does hormone replacement therapy improve outcomes in women with pulmonary hypertension?
Does hormone replacement therapy improve outcomes in women with pulmonary hypertension?
The literature reveals an 'estrogen paradox' in pulmonary hypertension, highlighting the urgent need for randomized controlled trials to determine whether hormone replacement therapy is beneficial or harmful in this population.
Answers are grounded in this paper and cite their sources.
PH management should prioritize underlying causes and symptoms; leaves open optimal strategies for advanced disease.
Pulmonary hypertension (PH) is a multifactorial condition that encompasses a group of diseases characterized by a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure and death. The primary goals of PH treatment are to lower pulmonary arterial pressure, alleviate symptoms such as shortness of breath and chest pain, address modifiable risk factors, and manage the underlying cause, often a common advanced disease like chronic obstructive lung disease or left heart disease. While sex is an unchangeable risk factor for PH development, the presence or absence of estrogens has a significant influence on its progression. Hormone replacement therapy (HRT) is the recommended form of estrogen therapy for postmenopausal women, but only in carefully selected cases. However, a paradox arises, as some research suggests HRT benefits women, while other studies highlight its risks. This review provides a comprehensive analysis of the literature on the role of HRT in PH.
No takes yet. Share an insight, caveat, or question.
Sohi et al. (2024) conducted a review in Pulmonary Hypertension. Hormone Replacement Therapy was evaluated. Current literature presents conflicting evidence on the use of hormone replacement therapy in pulmonary hypertension, with no consensus established due to a lack of randomized controlled trials.
Synapse has enriched 10 related papers. Consider them for comparative context: